Head and Neck Cancer
A Study of Prexasertib (LY2606368) with Chemotherapy and Radiation in Participants with Head and Neck Cancer
The main purpose of this study is to investigate the safety of prexasertib (LY2606368) in combination with other anti-cancer drugs (cisplatin or cetuximab) and radiation therapy in participants with locally advanced head and neck cancer. The study has two parts (A and B). Participants will only enroll in one part.
The results of this study are not yet available.
Your participation will last ~ 7-8 weeks depending on how well you tolerate therapy. There is also a follow up period of ~ 1 year.
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participant must have a diagnosis of head and neck squamous cell carcinoma of the oropharynx (tonsil, base of tongue, soft palate, or oropharyngeal walls), hypopharynx, or larynx
Participants of reproductive potential must agree to use medically approved contraceptive precautions during the study and for six months following the last dose of study drug
Female participants of childbearing potential must have negative pregnancy test and must not be breast feeding
Participant must not have received any of the following prior therapies or treatments: systemic therapy for the head and neck cancer, radiation therapy to the head and neck region, or curative-intent surgery in the head and neck region
Participant must not have an active symptomatic fungal, bacterial or viral infection, including HIV or Hepatitis A, B, or C
Participant must not have a serious heart condition, such as congestive heart failure, unstable angina pectoris, or have had a heart attack within the last three months